Elahere was found to improve survival in patients with FR-alpha–positive, platinum-resistant, high-grade serous epithelial ...
Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing ...
Committee for Human Medicinal Products (CHMP) recommended approval of five novel medicines at its September meeting ...
AbbVie (NYSE: ABBV) shares lost ground Friday. The company announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...
Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
AstraZeneca is continuing to study AZD8205 as a monotherapy in dose optimization expansion cohorts of patients with ...
Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...
Investors have rewarded ABBV stock thanks to the uptick in its sales despite the biosimilar competition for its blockbuster ...
Zacks.com on MSN16d
AbbVie Stock Up Almost 20% in 3 Months: Buy, Sell or Hold?AbbVie ABBV stock has gained 19.4% in the past three months compared with an increase of 8.1% for the industry. The stock has ...
MarketBeat on MSN16d
AbbVie Stock Post Humira is Still an Attractive Stock to HoldAbbVie (NYSE: ABBV) is a global biopharmaceutical company long synonymous with its blockbuster drug, Humira. While the drug's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback